Skip to Content

CAR T Cell Therapy – a new standard of care for 2L treatment of R/R in Large B-cell Lymfoma

Lisocabtagene Maraleucel, a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, has the potential as a new standard of care for 2L treatment in patients with R/R in Large B-cell Lymfoma. In this MEDtalk Manali Kamdar, Associate Professor of Medicine at the University of Colorado School of Medicine and Clinical Director of the lymphoma program, gives her perspective on the study: Lisocabtagene Maraleucel Therapy Versus Standard of Care with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation As Second-Line Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma.

Manali Kamdar

Lue artikkeli

Jos olet lääkäri, farmaseutti tai rajatun lääkkeenmääräämisoikeuden omaava sairaanhoitaja, pääset lukemaan artikkelin kirjautumalla käyttäjäksi BestPractice Nordic -sivustolle.

Back to top